Global Leader in Oral Delivery of Therapeutic Proteins
We are a clinical stage, global company, focused on high unmet clinical needs where oral delivery of a protein therapy can significantly improve the standard of care
ABOUT US
Entera is Daring Courageous Fierce
We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.
Therapeutic Areas
Osteoporosis
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.
LATEST NEWS
Press Releases
- November 29, 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
- May 3, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
Events
- September 9, 2022
